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Reduction of Primary Nonfunction With Prostaglandin E1 
After Clinical Liver Transplantation 
S. Takaya, H. Doyle, S. Todo, W. Irish, J.J. Fung, and T.E. Starzt 
~b use ofUW solution l has resulted in improved graft 
~ . function after transplantationz.J even with long aver-
age preservation times.4 However. although the incidence 
of primary nonfunction (PNF) has decreased, it remains a 
significant clinical problem. in part because the demand for 
livers has caused an increased use of previously discarded 
organs.' Greig et al6 have reported that prostaglandin E1 
(PGE I ) can ameliorate. or reverse. severe ischemic injury 
after liver transplantation. consistent with reports of several 
prostaglandin agents in experimental hepatic7- 1l and non-
hepatic l2•13 test models of ischemic injury. In addition, we 
have reported that the combination of PGE I plus high-dose 
steroids favorably influences the course of human liver 
allografts transplanted despite a positive Iymphocytotoxic 
cross match14 and that PGE, in cross-match negative cases 
reduces FK 506 nephrotoxicity. IS Consequently. we began 
in October 1991 to give PGE , perioperatively to all liver 
recipients with a subsequent very low (1.1 %) incidence of 
PNF in 174 consecutive negative cross-match cases. 
MATERIALS AND METHODS 
Case Material 
The study was of 174 consecutive adult primary liver recipients 
between November 1. 1991. and September 30. 1992-excluding 
cases with cross-match positive donors. multiple organ transplan-
tations. upper abdominal exenterations. and cases in which the liver 
was split (for two recipients) or surgically reduced in size. Histor-
ical controls with the same clinical characteristics and indusion 
criteria (Table 1) were treated between July 19. 1990. and October 
31. 1991 (n = 304). Patients of both the control (Group I) and 
study cohort (Group II) were iollowed unlil March I. 1993. 
Table 1. Features in 478 Primary Liver Transplantations 
Group I Group II 
Number of patients 304 174 
PGE, usage no yes 
Periods 7/19190- 11/01191-
10/31191 9130192 
Age (y) 49.3 = 0.7 51.0 = 0.96 
Sex 
Male/Female 1831121 107/67 
No. excluded for + cross match 29 (8.4%) 19 (9.3%) 
UNOS Score 4 108 (35.5%) 57 (32.8%) 
CIT (h:mtn) 14:18 = 0:14 14:36 = 0:15 
Longer than 20 h of CIT 25 (8.2%) 9(5.2%) 
More than 20 untts of blOOd 104 (34.1%) 63 (36.0%) 
transfusion 
Median days follow-up (range) 749 (497-956) 322 (157-492) 
CIT· Cold iSCllemlC time: means :: SE for age and CIT. 
Definition of Primary Nonfunction 
Thirty-day graft loss from all cases was 45/304 (14.8%) in Group I 
and 19/174 (10.9%) in Group II. defined either as patient death or 
retransplantation (Table 2). Muhiple factors frequently could be 
identified. but the dominant cause of failure was classified as shown 
in Table 2 including two examples of irreversible brain injury in 
patients with fulminant hepatic failure. Technical complications 
included hepatic artery thrombosis or stricture. portal vein throm-
bosis, hepatic veinivena cava stricture or thrombosis. and excessive 
transfusions (>50 units). 
A diagnosis of PNF was made when. in the absence of these 
other complications. a graft had no or nonlife-sustaining function 
within :! weeks of the initial transplant. The associated clinical 
picture included coagulopathy, failure to wake up, renal dysfunc-
tion. failure of the liver to initiate or maintain bile production, 
lactic acidosis. and hemodynamic instability. Histopathologically. 
the grafts usually showed small infarcts andior zonal hepatocellular 
coagulative necrosis (centrilobular or periportal) or severe cho-
lestasis subsequently without evidence of rejection. 
Table 2. Causes of Graft Failure Within 1 Month 
Group II 
Group I (PGE,) 
Number of primary grafts 304 (100%) 174" (100%) 
Causes of graft failure In 1 month 
Primary non function (PNF) 18 (5.9%) 2 (1.1%) 
Primary dysfunction 1 (0.3%) 0(0%) 
HAT, HA stricture. or PYr 12 (3.9%) 5 (2.9%) 
Other technical 4(1.3%) 3 (1.7%) 
Rejection 0(0%) 0(0%) 
Cardiac problems Including 1 (0.3%) 4(2.3%) 
pulmonary hypertension 
Infection. sepsis 7 (2.3%) 5(2.9%) 
Encephalopathy, brain death 2 (0.7%) 0(0%) 
Total no. of graft failures 45 (14.8%) 18 (10.9%) 
HAT 0 hepatic artenal thromboSIS; PVT = ponaj vetn thrombosiS. 
'Includes 4 patients who could not lolerate PGE,: They are In the C8tegones 
of Cardiac problems (n • 2). Other technIcal (n = 1 J. and PNF (n 2 1 J. 
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Organ Procurement and Preservation 
Hepatectomy was performed using standard techniques16 or with a 
modified rapid·Hush technique17 for unstable donors. Grafts were 
preserved with UW solution (ViaSpan. Du Pont Pharmaceuticals). 
When there was concern about the quality of a liver, a frozen 
Section biopsy was performed at the time of back-table preparation. 
The presence of severe macrovesicular steatosis (greater than 50% 
of hepatocytes), with or without hepatocellular necrosis.1 8•19 was a 
discard criterion applied uniformly in both groups. Cold ischemic 
time (ern for Group I ranged 4.1 to 29 hours (14.3 ::!: 0.29 [SED 
and for Group II it ranged 6.6 to 23.1 hours (14.6 :!: 0.30). The CIT 
exceeded 18 hours in 18.2% of Group I patients and in 15.7% of 
those in Group II. 
Management 
Immunosuppression. Intravenous FK 506 was begun in the op-
erating room and continued as a continuous infusion (0.1 to 0.05 
mglkg per day) until oral intake could be resumed. Doses were 
adjusted to achieve a target plasma level of 1 ngtmL with the 
method of Tamura:o in the immediate postoperative period. and a 
similar trough level after oral dosing every 12 hours was staned. 
Although the first-day IV dose was 0.1 mgt'kg per day in 88% of the 
Group I patients and 0.05 mgtkg per day in all patients of Group n. 
the rapid adjustments based on plasma momtoring made the 
cumulative doses equivalent. 
Patients in both groups received a single I g bolus of methyl-
prednisolone Intraoperatively and 20 mg d with conversion to the 
oral route as soon as this was feasible. Rejection episodes that were 
unresponsive to adjustments of FK 506 maintenance doses were 
treated With a single I g bolus of methylprednisolone. When 
rejection persisted. an additional 5·day tapering burst of methyl· 
prednisolone was given (from 200 mg down to 20 mg). or alterna-
tively a J- to 5·day course of OKTJ (5 to 10 mg/d). 
Proslaglandin £,. Prostaglandin E, (PGE,. Prostin·VR. Upjohn) 
was given as a continuous infUSion through a central venous 
catheter. starung at the time of surgery or immediately after its 
completion. Five hundred micrograms were dilutcd in 100 mL of 
5% dextrose In water. and started at a dose of 0.::' ILgikg per hour. 
which was gradually increased to (J.b ILg/kg per hour and main-
tained there for the next 5 to 7 Javs unless hypotension or 
cardiovascular Instabilitv necessitated an adjustment. 
Standard Funcl/on Tem. Treatment was guided bv the parame-
ters deSCribed above. which were correlated with standard liver 
function tests. Of these. bilirubin. alkaline phosphatase. gamma-
glutamyl tr:!nspepudase (gamma·CiTP). and tr:!nsammases (aspar-
tate aminotransferase IAST1. and alanine amlnOlf:lnsferase 
IALT]). and prothrombin time were given the greatest weight. 
Blood ammoOia. serum lactic aCId. and other speCial tests were 
spot-checked. Renal function was monltorcd WIth serum creatinine 
(Cr) and blood urea nllrogen (BUN). 
Arterial Ketone Body Ratio (AKBR) 
On days 0 through 5. the arten:!1 ketone bodv ratio (AKI3R) was 
measured within 40 minutes of artenal blood draWing (-lOlL) by an 
enzymatic technique based on the methods of I\kl1anbv and 
til·liamson~lK~~ using a Kctorex Kit (Sanwa ChemIcal Com pan\'. 
Ltd .. N:!gllva. Japan I and a KETO·:;-10 semiautOmatic spectropho-
tometer (Ihara Medics L'S. Inc. ValenCia. Calin. The acetoacetate 
and /3·hvdroxvbuMatc. irom which the AK13R IS c3kulated. are 
sigmficantlv elevated (> 100 !J.moliL) Wllh starvation. Consc· 
4uentlv. It should be noted th:!t the average pallent reccl\'ed sc; 
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dextrose in 0.45% normal saline at a rate.Qf 100 to 120 mUhour on 
the day of transplantation and on tht:-first postoperative day. 
Starting on postoperative day 2, patients usually received paren-
teral nutrition. which was continued until the enteral route could 
be used. With this treatment, starvation was observed in 12 patients 
(2.5%) on the first postoperative day. No hypoglycemia was 
encountered at the time of AKBR measurement. The AKBR 
results at 48 hours were placed into three categories: 
Class 1. AKBR > 1.0 
Oass 2. AKBR between 0.7 to 1.0 
Oass 3. AKBR < 0.7. 
Statistical Analysis 
Results were expressed as mean :!: SEM. The Kaplan-Meier 
(product limit) method was used to calculate graft survival. and the 
curves were compared with the generalized Wilcoxon (Breslow) 
test. One-way analysis of variance (ANOVA) was used to compare 
means across the three AKBR categories and stratified by PGE, 
use or nonuse. The Scheffe F-test was used as a post-hoc multiple 
comparison technique. Univariate logistiC regression analysis was 
used to evaluate independently the association among graft failure. 
primary nonfunction. and hepatic artenal thrombosis with PGE , 
usage. AKBR on day 2. peak prothrombin time. peak AST and 
ALT. magnitude of change in AST and AL T levels during the first 
24 hours. UNOS score. blood usage. and cold ischemic time. The 
strength of association of these factors on graft failure. pnmary 
nonfunction. and hepatic arterial thrombosis was estimated by the 
odds ratio. The significance of each odds ratio was tested using the 
Wald statistic. The one-way analysis of variance and chi·square 
tests were performed using the statistical package STATVIEW. 
while logistic regression analyses were performed using SPSS PC +. 
All tests of significance were two-tailed. with significance at a level 
of .05. 
RESULTS 
Patient and Graft Survival 
Patient. One-month survival in control Group I was 
1)6.4% vs lJ5.5% in the PGE,-treated Group II (NS). At the 
end of the year. the survival rate for the two cohorts was 
85.5% and 90.5o/c. respectively (NS) (Fig 1). 
Graft. At one month. 85.2% and 89.1 C;·c of the grafts wcre 
still in place in Groups I and II. respectively (NS). and at I 
year these survival percentages had fallen to T2.7C:C \'s 
il2.2% (P < .OS) (Fig I). 
Primary Nonfunction and Other Graft Losses 
PNF. The incidence of l.l '/i: in the PGE , group during 
the first:; weeks (Table 2) was significantly lower than 5.9cr 
in the controls (odds rallO = ll.ISS. P <OS). 
Otlrer Causes of Graft Lass (First MOil/II I. The pattern of 
!!raft loss from other c;\Uses was similar in hath groups 
including the inCIdence of vascular and nonvascular techni-
cal complications. No grafts were lost to reJcction in either 
whorl. 
The four pattents who could not tolerate PGE, were 
included in the "Intent to treat" analysis (Table 2). Three of 
the four lnst their !!rafts-one bv death. and one each to 
PNF and hepatic a;tcry thrombo~is followed by successtul 
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Months After Transplantation 
Fig 1. Patient and graft survIval rates after liver transplantation 
in Group I control and Group II (PGE,). A significantly better graft 
survival rate was observed in Group II patients with the usage of 
PGE, (Breslow. P < .05). 
retransplantation on postoperative days 2 and 3. respec-
tively. The fourth patient (who survived) had PG E, stopped 
because of excessive bleeding perioperatively. 
Unil'anale LogIStic Regression AnaZvsis. The PNF rate was 
not independently affected by UNOS classilication. volume 
of transfusion. and the minor differences in CIT (Table 3). 
However. PNF was associated with the peak transaminase 
values in the first 24 hours. prolonged early prothrombin 
times. and a low 48-hour AKBR (see also below). 
The global loss rate (from all causes) in the first month 
had the same associations as PNF with peak early transami-
nases. prothrombin time. Jnd AKBR. In addition. the 
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quantity of intraoperative transfusions emerged by 30 days 
as a signiticant risk factor (P = .Ol) (Table 3). 
AKBR and Prognosis 
The AKBR determinations lip to postoperative day 2 were 
available in only R3% of Group I and 90% of Group II 
patients. Because the incidence of PNF in the nonstudied 
patients of Group I (4/52) and Group II (0/17) was similar 
to that in the entire respective groups IP = .3). the culled 
cohorts were considered representative of the whole collec-
tion. 
Additional patients culled in roughly equal proportion 
from the control and study groups (Table 4) were 16 
requiring insulin for glucose control and 5 more with the 
clinical diagnosis of moderate or severe pancreatitis. In 
such cases. the prognostic significance of AKBR is lostK1gD;!~ 
We also excluded four patients from Group II that did not 
tolerate PGE , administration. Finally. 12 patients with the 
biochemical postoperative diagnosis of starvation could not 
be studied because the shift from glucose to fatty acid 
oxidation as the energy substrate in conditions of starvation 
distorts the meaning of the acetoacetatelB-hvdroxybutyrate 
measures upon which the calculations depend (see Materi-
als and Methods). This left 23H cases in Group I and 134 
cases in Group [[ with which <..it:tinitive anaiy~is of the 
prognostic significance of AKBR could be assessed (Table 
5). 
Group I. The control patients with good (Class 1) or 
moderately depressed AKBR (Class 2) had 96.6% and 
SO.8% I-month graft survival (P < .01). In contrast. all of 
the primary grafts were lost within a month in the 15 
patients with a 2-day AKBR <().7 (Class 3). The causes of 
Table 3. Analysis of Risk Factors for Primary Nonfunction and Arterial Thrombosis DUring First 2 Weeks and the Global Rate 
of Graft Failure in the First Month· 
Pnmary nontunctlon tor the tlrst 2 HepatIC anenal thrombOSIS for 
weeks the first 2 weeks Graft fadure for the tlrst month 
Untvanate analySIS OddS ratio P·value Odds ratio P·value Odds ratio P-vaJue 
Factors 
PGEI Usage 0.1884 .0246 0.7398 .5447 0.7055 .232 
AKBR at day 2 0.0008 ....:.00001 0.1095 .0014 0.017 <.00001 
Rise In AST in 1.0006 .0005 1.0001 .6656 1.0004 <.0001 
the first 24 h 
Rise In AL T in 1.002 ,0079 1.0001 .5411 1.0008 .0001 
the first 24 h 
Peak AST 1.0004 <.00001 1.0002 ,0052 1.0004 <.00001 
Peak ALT 1.0005 .00001 1.0002 .0295 1.0004 <.00001 
Prothrombin 1.2056 <.00001 1.0788 .0151 1.2069 <.00001 
time 
Cold ischemIC 4.1886 .3054 0.839 .906 3.261 .171 
time 
UNOS Score 4 1.5813 .3187 0.5299 .2014 0.9438 .8327 
Blood 0.9877 .4172 0.986 .437 1.012 .014 
transfusion y 
'UnlV8I13te loglSIIC regressIon analVSls. 
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Table 4. Exclusion From the AKBR Study 
G(OUP I 
No. of patients MBR 
('!fa) in day 2 
Diabetes mellitus 9 (3.6%) 0.71:: 0.12 
Pancreatitis 2 (0.8%) 0.94 :: 0.21 
Surgical starvation 3 (1.2%) 0.71 ::': 0.08 
No PGE, usage -(0%) 
Total no. of patients 14 (5.6%) 
graft loss in the Class 3 AKBR category were PNF (n = 8) 
and hepatic artery or portal vein thrombosis (n = 7). 
The AKBR cla'iSifications correlated well with the results 
of early AST and prothrombin-time measurements (Table 
5), which ranged from the least perturbed in the Class I 
patients to the most grave in the ill-fated Class 3 collection. 
Group II. The I-month graft survival of patients treated 
with PGE I was 96.8Cff for those with Class 1 AKBR and 
96.9% with the Class 2 designation (Table 4). The four 
losses (all with patient death) in these two categories was 
ascribed to sepsis (I! = 3) and a cardiac complication 
following a graft vena caval anastomosis to the host right 
atrium. Five (55'c) of the nine Class-3 grafts survived. The 
salvage in this third AKBR category vs the universal failure 
in the similar control patients who did not receive PGE I 
was significant (P < .01). The four organs lost in the Class 
Group I'(PGE,) 
No. of paltents AKBR 
PNF (%) in day 2 PNF 
1 7(4.5%) 0.84:: 0.03 a 
a 3 (1.9%) 1.09:: 0.23 a 
a 9(5.7%) 0.62::': 0.02 0 
0 4(2.5%) 0.76::,: 0.06 
23 (14.6%) 
3 category failed from PNF in a patient with coincident 
pulmonary hypertension (1/ = 1) or from hepatic artery 
thrombosis (1/ = 3). 
The better course in the PGEI-treated patients was not 
reflected in the early liver function tests. which were 
indistinguishable from those in the controls (Table 5). 
DISCUSSION 
The clinical importance of PNF is underscored by the 
recent report of the UNOS liver transplant registry of 5651' 
patients who received liver transplants in the United States 
from 19SH through the end of 1990.:5 Primary nonfunction 
was the single most frequent eause of graft failure. with a 
consequent mortality of 5.8%.:5·2/0 The highly variable 
incidence of this complication in different centers (ranging 
Table 5. Survival. Causes of Graft Failure. and Liver Function Tests Connected With Results ot Arterial Ketone Body Ratio (AKBR) 
in Patients With or Without PGE, 
Class I 
Range of AKBR AKBR;:, 1.0 
Number of primary grafts 145 
Graft survival at 1 month 140 (96.6%) 
Patient survival at 1 month 143 (98.6%) 
Causes of graft failure at 1 month 
Pnmary nonfunctlon 0 
Primary dysfunctIOn a 
HAT, HA stncture. and/or PVT 1 
Other techOical 0 
Rejection a 
Cardiac problems Including 2 
pulmonary hypenenslon 
Infection or sepsIs 2 
Encephalopathy. brain death 0 
Peak AST (lUll) 1607 ::': 13 
Rise in AST for the first 24 h (lUll) 1128::,: 45 
Peak PT (sec) 16.8 ::': 0.03 
CIT (him in) 13.49 
Range of CIT (him,", 4.08-27.21 
a: Class 1 vs Class 2 In group I P '" .005. 
b: Class 2 vs ClaSS J Tn group I P < .0001. 
Group I 
Class 2 
0.7 s AKBR < 1.0 
78 
63 (80.8%)" 
75 (97.3%) 
6 
2 
3 
1 
0 
0 
1 
2 
2852 :: 44°' 
212 ~ 78" 
20.2::: 0.1°' 
13.46 
4.43-27.38 
Group II (PGE,I 
Class 3 Class I Class 2 
AKBR < 0.7 AKBR " 1.0 0.7 s AKBR < 1.0 
15 93 32 
o (O%)b 90 (96.8%) 31 (96.9%) 
12 (80.0%) 91 (97.8%) 31 (96.9%) 
8 0 0 
0 0 0 
7 0 0 
0 0 0 
0 0 0 
0 0 
0 2 1 
0 0 0 
5836 ~ 352"- 1800::,: 18 2868:= 94 
2275 ::': 615· 868::: 14 108 ::': 98 
22.9 ::: 1.1" 16.7::: 0.03 20.1 :: 0.2"" 
14.52 14.20 14.09 
11.48-23.07 6.37-23.02 8.53-20.10 
c: Class 1 vs Class J Tn group II P ..;; .001: Class 2 vs Class 3 In group II P -: .01; Class 3 In group I vs Class 3 In group II P < .01. 
d: Peak AST In grouol': Class 1 vs class 2 P -: .01. #: Class 1 vs Class 3 P '" .01. +; Class 2 vs Class 3 P < .01. 
e: Peak AST In grouD II _: Class 1 vs Class 3 P < .01 . .,.; Class 2 vs Class 3 P < .01. 
f: Rise In AST In 9ro.::1 1'; Class 1 vs Class 2 P < .05. #: Class 1 vs Class 3 P < .01. +: Class 2 vs Class 3 P < .05. 
g: PT (protn(omOtn tl"''''lln group I': Class 1 vs Class 2 P < .05. #: Class 1 vs Class 3 P < .01. 
h: PT In group 11'. Class I vs Class 2 P <01. _: Class 1 vs Class 3 P <' .01. +: Class 2 vs Class 3 P < .01. 
HAT. hepatiC arlena: tnromoosls: PVT. ponal veIn tnromoosls. 
Class 3 
AKBR < 0.7 
9 
5 (55.6%)C 
9 (100%) 
1 
0 
3 
0 
0 
0 
0 
0 
6439 ~ 457···· 
649:: 313 
27.2 :: 1.0·-
13.53 
10.58 -19.06 
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from 20: to 231( ) probably reflects the lack of a generally 
accepted definition:'·::7.:x This is because PNF is a descrip-
tive term encompassing a variety of conditions that repre-
sent the common ultimate manifestations of a catastrophic 
liver injury. which by definition is irreversible. 
Etiologic factors ascribed to the donor include preexist-
ing liver diseasc. I " agonal ischemic episodes.:'1 the use of 
vasopressor support.:"'"'' intraoperativc manipulation. It, 
faulty procurement technique. and prolonged warm or cold 
ischemia time! Recipient factors could be cardiovascular 
instability after reperfusion:' I voluminous blood loss.3:: the 
need for pressor agentsKg~ endotoxemia.J : preformed anti-
graft antibodies.).l-Jh and perhaps. above all. an unrecog-
nized hostile immunologic environment that mav not be 
detectable with current screening methodolo~;KFT Such 
causal ambiguity and heterogenicity plus our previous dem-
onstration of the hepatic as well as renal benefits of 
prostaglandin-steroid therapy in liver recipients who had a 
positive lymphocvtotoxic cross match prompted our current 
policy of prophylactic PGE , therapy for all liver-transplant 
cases. I" 
In the present study of cross-match negative patients 
treated with PGE ,. in which an immediately precedent 
consecutive series of comparablt: cases was used as a 
control. the incidence of PNF appeared to have been almost 
eliminated. The incidence of 1.1 % (21174) was swollen to 
this figure by the "intent to treat" analysis. The incidence of 
PNF actually was 1/173 if the patient was excluded who was 
scheduled for but could not tolerate this therapy. 
This low rate of PNF in the PGE , series. as well as the 
relatively low incidence of 5_9% in the controls who did not 
receive PGE, therapy. reflected in part a strict definition of 
PNF and the deletion from the PNF list of livers lost to 
other complications (particularly technical errors). In addi-
tion. patients were excluded prospectively from entry into 
the study who had the positive cytotoxic cross matches that 
increase the risk of PNFJ4 unless much higher doses of 
steroids than in the cases herein reported are given in 
combination with PGE 1• 14 
The definable operative and early postoperative compli-
cations causing liver loss. and that are sometimes passed off 
as PNF. were not significantly benefitted by the PGE , 
treatment. In the culled remaining cases. the patients with 
an early postoperative course predicted to be favorable by 
the AKBR test appeared to have no need for prophylactic 
PGE , therapy. With this test, pioneered by Ozawa and 
Pichlmayr and their associates.3s.39 the redox potential 
(reduction-oxidation potential) of hepatic mitochondria is 
assessed by measuring the blood/arterial ketone body ratio 
(AKBR). Ozawa and Pichlmayr showed that an AKBR 
below 0.7 at 24 hours after organ recirculation was an early 
predictor of graft loss. More extensive later studies were 
provided by Asonuma et al40 who showed a close relation-
ship between ultimate graft prognosis and the 2- to 5-day 
AKBR. 
Patients who appeared to benefit from PGE 1 treatment 
were those with a moderate reduction of energy charge who 
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had an approximately 15('( gain in I-month graft survival 
and. above all. those with an AKBR below 0.7. In the latter 
group. five of nine grafts survived compared to none in the 
control group. Unfortunately. the AKBR is not discriminat-
ing in diabetic patients.:)':' recipients with pancreatitis (by 
inference). and probably patients with biochemical evi-
dence of starvation.41 Under these circumstances. the 
AKBR tends to underestimate graft quality. Thus. it cannot 
be wisely uscd as a routine unless it is interpreted by 
someone with knowledgc of its biochemical basis. 
The potential efficacy of PGE , in liver transplantation 
could be rationalized in so many ways that it is not tempting 
to fix upon a single explanation. Members of the prosta-
glandin family are cytoprotcctive for hepatocytes.K- 11 sup-
press cell-mediated cytotoxicity.4:.4) inhibit cytokine release 
from activating macrophages!4.4, facilitate hepatic regen-
eration.45 and inhibit superoxide anion radical El~ -) gen-
eration from activated polymorphonuclear leukocytes. 13 In 
addition. various prostaglandins are powerful vasodilators47 
and inhibit platelet aggregation!7 .• x although at a concen-
tration level that is 1000 times greater than the 100 pg 
measured in some of our patients receiving the highest dose 
of 0.6 /-lg/kg per hour (5. Takaya. unpublished observa-
tions ). 
The sharpest controversy is whether any or all of the 
foregoing mechanisms are as important in recovery from 
the insult leading to PNF as the vasodilation caused by the 
prostaglandins. In our patients with moderately or severely 
deranged AKBR. there was no evidence from the early liver 
function tests of AL T or prothrombin time of an amelio-
rating effect on the acutely damaged hepatocytes. Instead, 
the therapeutic effect was the inexplicably greater rate of 
ultimate recovery. Francavilla et al49 recently summarized 
the evidence that continuing microvascular failure is the 
reason for the liver's inability to recover from fulminant 
hepatic failure. rather than a paucity of growth or other 
factors subserving repair and regeneration. Thus. protec-
tion of the hepatic microvasculature is postulated to be the 
prime reason for a prostaglandin benefit not limited to its 
vasodilalOry effect. 7 .50 
Finally, the clinical use of PGE , as prophylaxis for liver 
injury has some inherent limitations. It is rapidly inactivated 
in the lung, making it difficult to deliver a high concentra-
tion to the desired target. It may cause hypotension under 
the already volatile cardiodynamic circumstances of liver 
transplantation. Other side effects are diarrhea as well as 
hypoxia due to exacerbation of pulmonary shunting. Nev-
ertheless, the benefits of prophylactic PGE1 for the liver 
transplant recipient would appear to outweigh its potential 
morbidity and inevitable inconvenience. 
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